1
|
Glasbey JC, Bundred J, Tyler R, Hunt J, Tattersall H, Gourevitch D, Almond LM, Desai AD, Ford SJ. The impact of postoperative radiological surveillance intensity on disease free and overall survival from primary retroperitoneal, abdominal and pelvic soft-tissue sarcoma. Eur J Surg Oncol 2021; 47:1771-1777. [PMID: 33549374 DOI: 10.1016/j.ejso.2021.01.021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 01/19/2021] [Accepted: 01/25/2021] [Indexed: 10/22/2022] Open
Abstract
AIM This observational study aimed to evaluate the impact of intensity of radiological surveillance on survival following resection of retroperitoneal sarcoma. METHOD Retrospective cohort study of patients undergoing primary resection of soft tissue sarcoma arising in the retroperitoneum, abdomen or pelvis at a single, high-volume sarcoma centre. Intensity of follow-up regimes up to 5 postoperative years were categorized as 'European Society for Medical Oncology (ESMO) compliant' (intense), or 'non-ESMO compliant' (less-intense). The primary outcome measure was overall survival (OS). The secondary outcome measures were disease-free survival (DFS) and reoperation rate. Analyses were stratified by high (grade 2 or 3) or low (grade 1) tumour grade. RESULTS Of 168 patients, 67.1% had high-grade and 32.9% had low-grade disease. Overall, 40.0% of patients had ESMO-compliant radiological follow-up (high-grade:25.7%, low-grade:66.7%). 41.7% of patients died and 48.2% suffered local or distant recurrence by cessation of follow up. Upon univariable analysis for high-grade tumours, ESMO compliance reduced DFS (p = 0.066) but had no impact on OS. There was no significant difference in the reoperation rate in patients with ESMO-compliant and non-compliant follow-up (p = 0.097). In low-grade tumours, ESMO compliance significantly reduced DFS (p < 0.001), but without effecting OS. In risk-adjusted models for high-grade tumours, ESMO compliant follow-up was associated with reduced OS (HR:3.47, 1.40-8.61, p = 0.007) and no difference in DFS. In low-grade tumours, there was no association between overall ESMO compliance and OS or DFS. CONCLUSION This study did not find a benefit for high-intensity radiological surveillance and overall survival in patients undergoing primary resection for high or low-grade retroperitoneal sarcoma.
Collapse
Affiliation(s)
- J C Glasbey
- Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, UK
| | - J Bundred
- Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, UK
| | - R Tyler
- Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, UK
| | - J Hunt
- Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, UK
| | - H Tattersall
- Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, UK
| | - D Gourevitch
- Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, UK
| | - L M Almond
- Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, UK
| | - A D Desai
- Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, UK
| | - S J Ford
- Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, UK.
| |
Collapse
|
2
|
Monteiro De Barros J, Hodson J, Glasbey J, Massey R, Rintoul-Hoad O, Chetan M, Desai A, Almond LM, Gourevitch D, Ford SJ, Strauss D, Smith H, Hayes A, Cardona K, Lopez-Aguiar A, Johnson A, Swallow C, Burtenshaw S, Nessim C, Weng R, Purgin B, Gronchi A, Fiore M, Callegaro D, Raut CP, Fairweather M, Bagaria S, Novak M, Gyorki D, Reid F, Mullinax J, Gonzalez RJ, Van Coevorden F, Van Houdt W, Haas RLM, Van Boven H, Heeres B. Intercontinental collaborative experience with abdominal, retroperitoneal and pelvic schwannomas. Br J Surg 2019; 107:452-463. [DOI: 10.1002/bjs.11376] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2019] [Revised: 07/09/2019] [Accepted: 08/30/2019] [Indexed: 11/09/2022]
Abstract
Abstract
Background
Schwannomas are rare tumours that pose a significant management challenge in the abdomen, retroperitoneum and pelvis. No data are available to inform management strategy.
Methods
A collaborative international cohort study, across specialist sarcoma units, was conducted to include adults presenting between 2000 and 2017 with histopathologically confirmed schwannomas within the abdomen, retroperitoneum or pelvis.
Results
Of 485 patients across 12 centres, 38 (7·8 per cent) were discharged without follow-up, 199 (41·0 per cent) underwent early resection and 248 (51·1 per cent) had radiological monitoring. Of these 248 patients, 96 (38·7 per cent) eventually had surgery, giving an overall resection rate of 60·8 per cent (295 of 485). At baseline, median tumour volume was 90·1 (i.q.r. 26·5–262·0) cm3. The estimated growth rate was 10·5 (95 per cent c.i. 9·4 to 11·6) per cent per year, and was consistent in the short term (within 2 years of diagnosis) and long term (beyond 2 years) (ρ = 0·405, P = 0·021). A decision to operate was more common in symptomatic patients (P < 0·001) and for rapidly growing tumours (growth rate more than 20 per cent per year) (P = 0·025). R0/R1 resection was achieved in 91·6 per cent of patients (263 of 287). Kaplan–Meier long-term recurrence rates after R0/R1 resection were 2·3 and 6·7 per cent at 3 and 5 years respectively.
Conclusion
Specific recommendations include: indications for early surgery, prediction of growth from radiological monitoring, promotion of selective submacroscopic resection and cessation of postoperative imaging surveillance.
Collapse
Affiliation(s)
| | | | - J Hodson
- Queen Elizabeth Hospital, Birmingham, UK
| | - J Glasbey
- Queen Elizabeth Hospital, Birmingham, UK
| | - R Massey
- Queen Elizabeth Hospital, Birmingham, UK
| | | | - M Chetan
- Queen Elizabeth Hospital, Birmingham, UK
| | - A Desai
- Queen Elizabeth Hospital, Birmingham, UK
| | - L M Almond
- Queen Elizabeth Hospital, Birmingham, UK
| | | | - S J Ford
- Queen Elizabeth Hospital, Birmingham, UK
| | | | - H Smith
- Royal Marsden Hospital, London, UK
| | - A Hayes
- Royal Marsden Hospital, London, UK
| | - K Cardona
- Emory University Hospital, Atlanta, Georgia, USA
| | | | - A Johnson
- Emory University Hospital, Atlanta, Georgia, USA
| | - C Swallow
- Mount Sinai Hospital, Toronto, Ontario, Canada
| | | | - C Nessim
- Ottawa Hospital Research Institute, Ottawa, Quebec, Canada
| | - R Weng
- Ottawa Hospital Research Institute, Ottawa, Quebec, Canada
| | - B Purgin
- Ottawa Hospital Research Institute, Ottawa, Quebec, Canada
| | - A Gronchi
- Istituto Nazionale dei Tumori, Milan, Italy
| | - M Fiore
- Istituto Nazionale dei Tumori, Milan, Italy
| | | | - C P Raut
- Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - M Fairweather
- Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - S Bagaria
- Mayo Clinic, Jacksonville, Florida, USA
| | - M Novak
- Institute of Oncology Ljubljana, Ljubljana, Slovenia
| | - D Gyorki
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - F Reid
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - J Mullinax
- Moffitt Cancer Centre, Tampa, Florida, USA
| | | | | | - W Van Houdt
- Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - R L M Haas
- Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - H Van Boven
- Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - B Heeres
- Netherlands Cancer Institute, Amsterdam, the Netherlands
| |
Collapse
|
3
|
Almond LM, Tirotta F, Tattersall H, Hodson J, Cascella T, Barisella M, Marchianò A, Greco G, Desai A, Ford SJ, Gronchi A, Fiore M, Morosi C. Diagnostic accuracy of percutaneous biopsy in retroperitoneal sarcoma. Br J Surg 2019; 106:395-403. [DOI: 10.1002/bjs.11064] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Revised: 06/10/2018] [Accepted: 10/30/2018] [Indexed: 12/20/2022]
Abstract
Abstract
Background
Percutaneous biopsy is recommended before surgery for suspected retroperitoneal sarcoma (RPS) to confirm the histological diagnosis and guide surgical strategy. The present study aimed to establish the diagnostic accuracy of percutaneous core biopsy with respect to histological diagnosis and tumour grade.
Methods
Data on patients with suspected RPS who underwent percutaneous biopsy followed by surgical resection between 2005 and 2016 at one of two tertiary European sarcoma units were reviewed. Histological tumour type and tumour grade on biopsy were correlated with postoperative histology to evaluate diagnostic accuracy.
Results
A total of 239 patients underwent percutaneous core biopsy followed by surgical resection in Milan (163, 68·2 per cent) or Birmingham (76, 31·8 per cent). Diagnostic accuracy varied with histological diagnosis (P < 0·001), but demonstrated overall concordance with final pathology following resection in 67·2 per cent of biopsies (κ = 0·606). The majority of discrepancies occurred in dedifferentiated liposarcoma (DDLPS), owing to under-recognition of dedifferentiation in this group. Concordance between pathology on biopsy and resection improved to 81·1 per cent when DDLPS and well differentiated liposarcoma were grouped together as liposarcoma. Grade on biopsy was concordant with grade on resection specimen in 60·4 per cent of tumours (κ = 0·640). Diagnosis of high-grade tumours on biopsy had a high specificity (98 per cent), and moderate positive predictive value (85 per cent) and negative predictive value (78 per cent).
Conclusion
A diagnosis of DDLPS or leiomyosarcoma on percutaneous biopsy is highly reliable. High-grade sarcomas can be identified with high specificity, which opens the door to a study on neoadjuvant therapy in these patients.
Collapse
Affiliation(s)
- L M Almond
- Department of Sarcoma and General Surgery, Midlands Abdominal and Retroperitoneal Sarcoma Unit, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
| | - F Tirotta
- Department of Sarcoma Surgery, Istituto Nazionale Tumori, Milan, Italy
| | - H Tattersall
- Department of Sarcoma and General Surgery, Midlands Abdominal and Retroperitoneal Sarcoma Unit, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
| | - J Hodson
- Department of Medical Statistics, Institute of Translational Medicine, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
| | - T Cascella
- Department of Radiology, Istituto Nazionale Tumori, Milan, Italy
| | - M Barisella
- Department of Radiology, Istituto Nazionale Tumori, Milan, Italy
| | - A Marchianò
- Department of Radiology, Istituto Nazionale Tumori, Milan, Italy
| | - G Greco
- Department of Radiology, Istituto Nazionale Tumori, Milan, Italy
| | - A Desai
- Department of Sarcoma and General Surgery, Midlands Abdominal and Retroperitoneal Sarcoma Unit, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
| | - S J Ford
- Department of Sarcoma and General Surgery, Midlands Abdominal and Retroperitoneal Sarcoma Unit, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
| | - A Gronchi
- Department of Sarcoma Surgery, Istituto Nazionale Tumori, Milan, Italy
| | - M Fiore
- Department of Sarcoma Surgery, Istituto Nazionale Tumori, Milan, Italy
| | - C Morosi
- Department of Radiology, Istituto Nazionale Tumori, Milan, Italy
| |
Collapse
|
4
|
Old OJ, Lloyd GR, Nallala J, Isabelle M, Almond LM, Shepherd NA, Kendall CA, Shore AC, Barr H, Stone N. Rapid infrared mapping for highly accurate automated histology in Barrett's oesophagus. Analyst 2018; 142:1227-1234. [PMID: 27713951 DOI: 10.1039/c6an01871h] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Barrett's oesophagus (BE) is a premalignant condition that can progress to oesophageal adenocarcinoma. Endoscopic surveillance aims to identify potential progression at an early, treatable stage, but generates large numbers of tissue biopsies. Fourier transform infrared (FTIR) mapping was used to develop an automated histology tool for detection of BE and Barrett's neoplasia in tissue biopsies. 22 oesophageal tissue samples were collected from 19 patients. Contiguous frozen tissue sections were taken for pathology review and FTIR imaging. 45 mid-IR images were measured on an Agilent 620 FTIR microscope with an Agilent 670 spectrometer. Each image covering a 140 μm × 140 μm region was measured in 5 minutes, using a 1.1 μm2 pixel size and 64 scans per pixel. Principal component fed linear discriminant analysis was used to build classification models based on spectral differences, which were then tested using leave-one-sample-out cross validation. Key biochemical differences were identified by their spectral signatures: high glycogen content was seen in normal squamous (NSQ) tissue, high glycoprotein content was observed in glandular BE tissue, and high DNA content in dysplasia/adenocarcinoma samples. Classification of normal squamous samples versus 'abnormal' samples (any stage of Barrett's) was performed with 100% sensitivity and specificity. Neoplastic Barrett's (dysplasia or adenocarcinoma) was identified with 95.6% sensitivity and 86.4% specificity. Highly accurate pathology classification can be achieved with FTIR measurement of frozen tissue sections in a clinically applicable timeframe.
Collapse
Affiliation(s)
- O J Old
- Gloucestershire Hospitals NHS Foundation Trust, Gloucester, GL1 3NN, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Glasbey JC, Arshad F, Almond LM, Vydianath B, Desai A, Gourevitch D, Ford SJ. Gastrointestinal manifestations of extramedullary plasmacytoma: a narrative review and illustrative case reports. Ann R Coll Surg Engl 2018; 100:371-376. [PMID: 29692194 DOI: 10.1308/rcsann.2018.0015] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Introduction Solitary extramedullary plasmacytoma are rare, solid-mass tumours which appear immunophenotypically similar to multiple myeloma. The diagnosis and management of gastrointestinal plasmacytoma is complex and requires multidisciplinary input. This study presents a narrative review of intra-abdominal extramedullary plasmacytoma, illustrated with two case studies. Methods The PubMed database was searched without date restrictions for reports of intra-abdominal extramedullary plasmacytoma to synthesise a narrative review. Electronic records were reviewed at a high-volume, quaternary soft-tissue sarcoma centre to identify patients with histopathologically confirmed extramedullary plasmacytoma affecting the gastrointestinal tract. Results Gastrointestinal extramedullary plasmacytomas can present with mass effect or organ-specific dysfunction. Techniques for tissue diagnosis of extramedullary plasmacytoma vary dependent on location, with a formal diagnosis often being made from a resected specimen. Management can include surgery, radiotherapy, systemic chemotherapy or a combination. No high-quality evidence base exists to guide treatment. Two case studies of operated gastrointestinal extramedullary plasmacytoma are presented at different phases of disease progression, with a resultant impact on survival. Conclusion Intra-abdominal extramedullary plasmacytoma is a rare and heterogeneous condition that lacks consensus guidelines for diagnosis and management. Collaboration between international specialist centres will create better quality evidence for treatment of this cohort.
Collapse
Affiliation(s)
- J C Glasbey
- Department of Soft Tissue Sarcoma, Queen Elizabeth Hospital , Birmingham , UK
| | - F Arshad
- Department of Soft Tissue Sarcoma, Queen Elizabeth Hospital , Birmingham , UK
| | - L M Almond
- Department of Soft Tissue Sarcoma, Queen Elizabeth Hospital , Birmingham , UK
| | - B Vydianath
- Department of Histopathology, Queen Elizabeth Hospital , Birmingham , UK
| | - A Desai
- Department of Soft Tissue Sarcoma, Queen Elizabeth Hospital , Birmingham , UK
| | - D Gourevitch
- Department of Soft Tissue Sarcoma, Queen Elizabeth Hospital , Birmingham , UK
| | - S J Ford
- Department of Soft Tissue Sarcoma, Queen Elizabeth Hospital , Birmingham , UK
| |
Collapse
|
6
|
Almond LM, Charalampakis V, Mistry P, Naqvi M, Hodson J, Lafaurie G, Matthews J, Singhal R, Super P. Corrigendum to "An "all 5 mm ports" technique for laparoscopic day-case anti-reflux surgery: A consecutive case series of 205 patients" [Int. J. Surg. 35 (2016) 214-217]. Int J Surg 2017; 41:214. [PMID: 28366606 DOI: 10.1016/j.ijsu.2017.03.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- L M Almond
- Department of Upper Gastrointestinal Surgery, Heart of England NHS Foundation Trust, United Kingdom.
| | - V Charalampakis
- Department of Upper Gastrointestinal Surgery, Heart of England NHS Foundation Trust, United Kingdom
| | - P Mistry
- Department of Upper Gastrointestinal Surgery, Heart of England NHS Foundation Trust, United Kingdom
| | - M Naqvi
- Department of Upper Gastrointestinal Surgery, Heart of England NHS Foundation Trust, United Kingdom
| | - J Hodson
- Department of Medical Statistics, University of Birmingham, United Kingdom
| | - G Lafaurie
- Department of Upper Gastrointestinal Surgery, Heart of England NHS Foundation Trust, United Kingdom
| | - J Matthews
- Department of Upper Gastrointestinal Surgery, Heart of England NHS Foundation Trust, United Kingdom
| | - R Singhal
- Department of Upper Gastrointestinal Surgery, Heart of England NHS Foundation Trust, United Kingdom
| | - P Super
- Department of Upper Gastrointestinal Surgery, Heart of England NHS Foundation Trust, United Kingdom
| |
Collapse
|
7
|
Abstract
Endoscopic surveillance remains the core management of non-dysplastic Barrett's oesophagus, although questions regarding its efficacy in reducing mortality from oesophageal adenocarcinoma have yet to be definitively answered, and randomised trial data are awaited. One of the main goals of current research is to achieve risk stratification, identifying those at high risk of progression. The recent British Society of Gastroenterology (BSG) guidelines on surveillance have taken a step in this direction with interval stratification on clinicopathological grounds. The majority of Barrett's oesophagus remains undiagnosed, and this has led to investigation of methods of screening for Barrett's oesophagus, ideally non-endoscopic methods capable of reliably identifying dysplasia. Chemoprevention to prevent progression is currently under investigation, and may become a key component of future treatment. The availability of effective endotherapy means that accurate identification of dysplasia is more important than ever. There is now evidence to support intervention with radiofrequency ablation (RFA) for low-grade dysplasia (LGD), but recent data have emphasised the need for consensus pathology for LGD. Ablative treatment has become well established for high-grade dysplasia, and should be employed for flat lesions where there is no visible abnormality. Of the ablative modalities, RFA has the strongest evidence base. Endoscopic resection should be performed for all visible lesions, and is now the treatment of choice for T1a tumours. Targeting those with high-risk disease will, hopefully, lead to efficacious and cost-effective surveillance, and the trend towards earlier intervention to halt progression gives cause for optimism that this will ultimately result in fewer deaths from oesophageal adenocarcinoma.
Collapse
Affiliation(s)
- O J Old
- Biophotonics Research Unit, Gloucestershire Royal Hospital, Gloucestershire Hospitals NHS Trust, Gloucester, UK,Upper GI Surgery Department, Gloucestershire Royal Hospital, Gloucestershire Hospitals NHS Trust, Gloucester, UK
| | - L M Almond
- Upper GI Surgery Department, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK
| | - H Barr
- Biophotonics Research Unit, Gloucestershire Royal Hospital, Gloucestershire Hospitals NHS Trust, Gloucester, UK,Upper GI Surgery Department, Gloucestershire Royal Hospital, Gloucestershire Hospitals NHS Trust, Gloucester, UK
| |
Collapse
|
8
|
Oliphant Z, Snow A, Knight H, Barr H, Almond LM. Endoscopic resection with or without mucosal ablation of high grade dysplasia and early oesophageal adenocarcinoma--long term follow up from a regional UK centre. Int J Surg 2014; 12:1148-50. [PMID: 25234253 DOI: 10.1016/j.ijsu.2014.09.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2014] [Accepted: 09/03/2014] [Indexed: 01/10/2023]
Abstract
BACKGROUND Endoscopic resection (ER) is emerging as a curative technique in patients with high-grade dysplasia (HGD), intramucosal cancer (IMC), and early submucosal cancer (T1sm1) within Barrett's oesophagus. METHODS This consecutive case series of 72 patients with HGD or IMC reports outcomes of ER, with or without mucosal ablation, in a single institution after a median of 38 months follow-up between 2004 and 2011. The primary outcome was disease progression to submucosal invasion. Secondary outcomes included disease regression, the effect of ER on staging compared to biopsy and procedure-related complications. RESULTS 72 patients (mean age 73.0 - range 52.0-93.0) were treated by ER ± ablative therapy with curative intent for HGD (88% patients) or IMC (12%). 38% had one or more severe systemic co-morbidities. A median of 4 (1-11) procedures were undertaken per patient. In addition to ER, 43% of patients were treated with argon plasma coagulation, 17% with radiofrequency ablation, and 11% with photodynamic therapy. 8 (13%) patients with HGD at baseline and 0 (0%) with IMC progressed to invasive carcinoma. The median time to progression was 26.3 and 12.6 months respectively. 51% patients experienced disease regression. Disease staging was upgraded by ER in 27% of patients. DISCUSSION This case series reports on a minimally invasive technique in an elderly population with multiple co-morbidities, demonstrating disease regression with long-term follow-up. CONCLUSION ER ± ablation is an effective and potentially curative option for patients with HGD or IMC. The benefit of endoscopic resection for disease staging was clearly demonstrated.
Collapse
Affiliation(s)
- Zoe Oliphant
- Department of Oesophagogastric and General Surgery, Gloucestershire Hospitals NHS Trust, Gloucester, UK.
| | - Alec Snow
- Department of Oesophagogastric and General Surgery, Gloucestershire Hospitals NHS Trust, Gloucester, UK
| | - Hannah Knight
- Department of Oesophagogastric and General Surgery, Gloucestershire Hospitals NHS Trust, Gloucester, UK
| | - Hugh Barr
- Department of Oesophagogastric and General Surgery, Gloucestershire Hospitals NHS Trust, Gloucester, UK
| | - L M Almond
- Department of Oesophagogastric and General Surgery, Gloucestershire Hospitals NHS Trust, Gloucester, UK
| |
Collapse
|
9
|
Almond LM, Hodson J, Barr H. Meta-analysis of endoscopic therapy for low-grade dysplasia in Barrett's oesophagus. Br J Surg 2014; 101:1187-95. [DOI: 10.1002/bjs.9573] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2013] [Revised: 10/25/2013] [Accepted: 04/24/2014] [Indexed: 12/20/2022]
Abstract
Abstract
Background
The optimal management of patients with Barrett's-associated low-grade dysplasia (LGD) is unclear. The objective of this study was to identify systematically all reports of endoscopic treatment of LGD, and to assess outcomes in terms of disease progression, eradication of dysplasia and intestinal metaplasia, and complication rates.
Methods
A systematic review of articles reporting endoscopic treatment of LGD was conducted in accordance with PRISMA guidelines. MEDLINE and Embase databases were searched to identify the relevant literature. Rates of complete eradication of intestinal metaplasia (CE-IM) and dysplasia (CE-D) were reported. The pooled incidence of progression to cancer was calculated following endoscopic therapy.
Results
Thirty-seven studies met the inclusion criteria, reporting outcomes of endoscopic therapy for 521 patients with LGD. The pooled incidence of progression to cancer was 3·90 (95 per cent confidence interval (c.i.) 1·27 to 9·10) per 1000 patient-years. CE-IM and CE-D were achieved in 67·8 (95 per cent c.i. 50·2 to 81·5) and 88·9 (83·9 to 92·5) per cent of patients respectively. The commonest adverse event was stricture formation.
Conclusion
Reports of endoscopic therapy were heterogeneous and follow-up periods were short. There is a high likelihood of historical overdiagnosis of LGD. Endoscopic therapy, particularly radiofrequency ablation, appears safe and effective at eradicating LGD, but does not eliminate the risk of progression to cancer.
Collapse
Affiliation(s)
- L M Almond
- Department of Upper Gastrointestinal Surgery, Gloucestershire Royal Hospital, Gloucester, UK
| | - J Hodson
- Wolfson Computer Laboratory, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
| | - H Barr
- Department of Upper Gastrointestinal Surgery, Gloucestershire Royal Hospital, Gloucester, UK
| |
Collapse
|
10
|
Machavaram KK, Almond LM, Rostami-Hodjegan A, Gardner I, Jamei M, Tay S, Wong S, Joshi A, Kenny JR. A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease–Drug Interactions: Suppression of CYP3A by IL-6. Clin Pharmacol Ther 2013; 94:260-8. [DOI: 10.1038/clpt.2013.79] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2013] [Accepted: 03/27/2013] [Indexed: 11/09/2022]
|
11
|
Affiliation(s)
- JML Williamson
- Department of Surgery, Bristol Royal Infirmary, Bristol BS2 8HW
| | - LM Almond
- Department of Oesophagogastric Surgery, Gloucestershire Royal Hospital, Gloucester
| | - NA Shepherd
- Histopathology, Gloucestershire Cellular Pathology Laboratory, Cheltenham General Hospital, Cheltenham, Gloucestershire
| | - H Barr
- Surgery in the Department of Oesophagogastric Surgery, Gloucestershire Royal Hospital, Gloucester
| |
Collapse
|
12
|
Abstract
The term postcholecystectomy syndrome (PCS) comprises a heterogeneous group of symptoms and findings in patients who have previously undergone cholecystectomy. Although rare, these patients may present with abdominal pain, jaundice or dyspeptic symptoms. Many of these complaints can be attributed to complications including bile duct injury, biliary leak, biliary fistula and retained bile duct stones. Late sequelae include recurrent bile duct stones and bile duct strictures. With the number of cholecystectomies being performed increasing in the laparoscopic era the number of patients presenting with PCS is also likely to increase. We briefly explore the syndrome and its main aetiological theories.
Collapse
Affiliation(s)
- S S Jaunoo
- Department of General Surgery, Worcestershire Royal Hospital, Worcester, UK.
| | | | | |
Collapse
|
13
|
|
14
|
Almond LM, Yang J, Jamei M, Tucker GT, Rostami-Hodjegan A. Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab 2009; 10:420-32. [PMID: 19519348 DOI: 10.2174/138920009788498978] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Although CYP induction is not generally considered to be as clinically relevant as CYP inhibition, there are important examples where induction has caused both therapeutic failure, due to insufficient exposure to parent drug, and toxicity, mediated by increased formation of reactive metabolites. Furthermore, while there has been considerable progress in the extrapolation of in vitro data to predict the in vivo consequences of enzyme inhibition, less attention has been given to the quantitative impact of enzyme induction as a mechanism of drug-drug interaction (DDI) and as a component of compound selection and early drug development. We discuss current approaches in the context of a mechanistic framework for the prediction of the extent and time-course of enzyme induction in vivo based on in vitro experimentation. Factors influencing the extent of DDI due to CYP induction are summarised, and areas deficient in information that would allow more accurate prediction within target populations are highlighted.
Collapse
Affiliation(s)
- L M Almond
- Simcyp Limited, John Street, Sheffield, UK.
| | | | | | | | | |
Collapse
|
15
|
Abstract
Intradural disc herniation is a well-recognized entity in the lumbar region, where over 90% of all intradural herniations are seen.1 By contrast, fewer than 5% occur in either the cervical or thoracic regions.1 We describe a case of a sudden onset neurological deficit caused by an intradural thoracic disc herniation at the T11-T12 level, the intradural nature of which was not diagnosed on preoperative MRI. To the best of our knowledge this is the first description of an intradural disc herniation at this level.
Collapse
Affiliation(s)
- L M Almond
- Department of Neurosurgery, Birmingham Children's Hospital, UK
| | | | | |
Collapse
|